Luspatercept

Generic Name: Luspatercept

Brand Names: Reblozyl

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1373715-00-4

Unique Ingredient Identifier: AQK7UBA1LS

Background: Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood transfusions. Lu...

Indication: Luspatercept is indicated for the treatment of:

Associated Conditions: Anemia

Associated Therapies: -

Clinical Trials

A Real-World Study of Β-Thalassemia Major Treatment with Luspatercept in Taiwan

Recruiting

Conditions: β-Thalassemia Major

Interventions: Drug: Luspatercept

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 90

Registration Number: NCT06596642

Locations: 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳
MacKay Memorial Hospital, Taipei, Taiwan

and more 2 locations

A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

Withdrawn

Conditions: Myelodysplastic Syndromes (MDS)

Interventions: Drug: Epoetin Alfa
Drug: Luspatercept

First Posted Date: 2024-08-30

Last Posted Date: 2024-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 86

Registration Number: NCT06581055

Locations: 🇨🇳
National Taiwan University Hospital (NTUH), Taipei, Taiwan

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

Phase 2

Not yet recruiting

Conditions: Primary Myelofibrosis
Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

Interventions: Drug: Momelotinib
Drug: Luspatercept

First Posted Date: 2024-07-24

Last Posted Date: 2024-07-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 56

Registration Number: NCT06517875

Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA

Phase 4

Not yet recruiting

Conditions: Aplastic Anemia

Interventions: Drug: Luspatercept
Drug: cyclosporine

First Posted Date: 2024-05-22

Last Posted Date: 2024-05-22

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 58

Registration Number: NCT06424639

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Luspatercept in Metastatic AGCT of the Ovary

Not Applicable

Completed

Conditions: Adult Granulosa Cell Tumor of the Ovary

Interventions: Drug: Luspatercept

First Posted Date: 2024-02-12

Last Posted Date: 2024-02-12

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 1

Registration Number: NCT06254781

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia

Not Applicable

Recruiting

Conditions: Effect of Drug

Interventions: Drug: luspatercept

First Posted Date: 2023-12-11

Last Posted Date: 2023-12-22

Lead Sponsor: Hematology department of the 920th hospital

Target Recruit Count: 10

Registration Number: NCT06164821

Locations: 🇨🇳
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan, China

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Early Phase 1

Recruiting

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Luspatercept

First Posted Date: 2023-11-02

Last Posted Date: 2024-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06113302

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia

Recruiting

Conditions: Myelodysplastic Syndrome
Beta Thalassemia

Interventions: Drug: Luspatercept

First Posted Date: 2023-10-10

Last Posted Date: 2024-11-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 104

Registration Number: NCT06073860

Locations: 🇰🇷
Local Institution - 0001, Seoul, Korea, Republic of
🇰🇷
Novotech Laboratory Korea Co., Ltd., Seoul, Korea, Republic of

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

Phase 3

Recruiting

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Luspatercept

First Posted Date: 2023-09-21

Last Posted Date: 2024-12-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT06045689

Locations: 🇩🇪
Klinikum rechts der Isar der Technischen Universitaet Muenchen, München, Bayern, Germany
🇮🇹
Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli - PO Riuniti, Reggio Calabria, Calabria, Italy
🇪🇸
Hospital Universitario Germans Trias i Pujol, Barcelona, Spain

and more 61 locations

Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS

Phase 4

Not yet recruiting

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Roxadustat
Drug: Luspatercept

First Posted Date: 2023-08-23

Last Posted Date: 2023-08-23

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 62

Registration Number: NCT06006949

Locations: 🇨🇳
Peking union medical college hospital, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy